fda deadline for semaglutide Approves Wegovy Weight-Loss Pill The FDA recently removed semaglutide

22 BuhlR.JaffeH

Clinical studies : A 2024 cohort study in JAMA Ophthalmology reported a higher observed rate of NAION in patients prescribed semaglutide compared with those on non-GLP-1 therapies, suggesting an increased risk but not proving causation

You have significant nausea, vomiting, constipation, poor intake, or dehydration symptoms

Higher doses are associated with greater appetite suppression and more pronounced gastrointestinal effects, both of which can prolong fatigue

doi:10.1016/S0140-6736(23)00374-0 JAMA Editorial

Fatigue can occur with dual incretin medication, although digestive side effects such as nausea, diarrhea, and constipation are more common